Detalhe da pesquisa
1.
Type I interferon and cancer.
Immunol Rev
; 321(1): 115-127, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37667466
2.
Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients.
Haematologica
; 105(7): 1868-1878, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31582537
3.
Interferon signaling restrains renal cell carcinoma heterogeneity.
Trends Cancer
; 9(11): 871-873, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37658022
4.
Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients.
Cell Death Dis
; 14(3): 209, 2023 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36964168
5.
Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents.
Trends Cancer
; 8(5): 426-444, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35181272
6.
Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines.
Oncoimmunology
; 11(1): 2101596, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35898703
7.
TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients.
Oncoimmunology
; 10(1): 1889822, 2021 03 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33758676
8.
Assessment of NK cell-mediated cytotoxicity by flow cytometry after rapid, high-yield isolation from peripheral blood.
Methods Enzymol
; 631: 277-287, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31948552